Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 24334029)

1.

Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.

Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K.

Mol Immunol. 2014 Mar;58(1):132-8. doi: 10.1016/j.molimm.2013.11.017. Epub 2013 Dec 14.

2.

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.

Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, Shida-Kawazoe M, Hattori K.

MAbs. 2013 Mar-Apr;5(2):229-36. doi: 10.4161/mabs.23452. Epub 2013 Feb 13.

3.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.

PMID:
23872058
4.

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.

Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, Leng E, Sweet H, Foltz I, Howard M, Rousseau AM, Kozlosky C, Fanslow W, Yan W.

J Biol Chem. 2014 Feb 7;289(6):3571-90. doi: 10.1074/jbc.M113.513366. Epub 2013 Dec 5.

5.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].

6.

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).

Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K.

Protein Eng Des Sel. 2013 Oct;26(10):589-98. doi: 10.1093/protein/gzt022. Epub 2013 Jun 5.

7.

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV.

J Clin Invest. 2014 Feb;124(2):725-9. doi: 10.1172/JCI72676. Epub 2014 Jan 9.

8.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
9.

Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.

Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):604-9. doi: 10.1073/pnas.0908590107. Epub 2009 Dec 18.

10.

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.

Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umaña P, Benz J.

Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12669-74. doi: 10.1073/pnas.1108455108. Epub 2011 Jul 18.

11.

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H.

J Immunol. 2010 Dec 1;185(11):6876-82. doi: 10.4049/jimmunol.1002600. Epub 2010 Nov 1.

12.

Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies.

Yu X, Baruah K, Harvey DJ, Vasiljevic S, Alonzi DS, Song BD, Higgins MK, Bowden TA, Scanlan CN, Crispin M.

J Am Chem Soc. 2013 Jul 3;135(26):9723-32. doi: 10.1021/ja4014375. Epub 2013 Jun 25.

13.

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.

Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR.

Mol Cancer Ther. 2008 Aug;7(8):2517-27. doi: 10.1158/1535-7163.MCT-08-0201.

14.

Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.

Nagashima H, Tezuka T, Tsuchida W, Maeda H, Kohroki J, Masuho Y.

Mol Immunol. 2008 May;45(10):2752-63. doi: 10.1016/j.molimm.2008.02.003. Epub 2008 Mar 18.

PMID:
18353438
15.

IgG2m4, an engineered antibody isotype with reduced Fc function.

An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, Harvey BR, Montgomery D, Zaller D, Wang F, Strohl W.

MAbs. 2009 Nov-Dec;1(6):572-9.

16.

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.

Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, Lazar GA, Schneider-Merck T, Peipp M, Valerius T.

Cancer Sci. 2010 May;101(5):1080-8. doi: 10.1111/j.1349-7006.2010.01505.x. Epub 2010 Jan 20.

PMID:
20331636
17.

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS.

Mol Immunol. 2007 Mar;44(7):1524-34. Epub 2006 Oct 11.

PMID:
17045339
18.
19.

Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.

Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.

J Immunol Methods. 2011 Feb 28;365(1-2):132-41. doi: 10.1016/j.jim.2010.12.014. Epub 2010 Dec 23.

PMID:
21185301
20.

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.

Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE.

Blood. 2009 Apr 16;113(16):3735-43. doi: 10.1182/blood-2008-10-182048. Epub 2008 Dec 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk